NerveCheck: An inexpensive quantitative sensory testing device for patients with diabetic neuropathy  by Ponirakis, G. et al.
NerveCheck: An inexpensive quantitative sensory
testing device for patients with diabetic neuropathy
G. Ponirakis a,c, M.N. Odriozola b, S. Odriozola b, I.N. Petropoulos a,c,
S. Azmi c, H. Fadavi c, U. Alam c, O. Asghar c, A. Marshall c, A. Miro b,
A. Kheyami c, A. Al-Ahmar c, M.B. Odriozola b, A. Odriozola d,e,
R.A. Malik a,c,*
aWeill Cornell Medical College in Qatar, Research Division, Qatar Foundation, Education City, PO. Box 24144, Doha,
Qatar
b Phi Med Europe Barcelona, Department of Electronics Engineering, Barcelona, Spain
c Institute of Human Development, Centre for Endocrinology & Diabetes, Faculty of Medical and Human Sciences,
University of Manchester and NIHR/Wellcome Trust Clinical Research Facility, Manchester M13 9NT, UK
d ICEN, Catalonian Institute of Endocrinology and Nutrition, Medical Centre, Barcelona, Spain
eEndocrinology Department, Hospital Clinic Universitario de Barcelona, Spain
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 3 ( 2 0 1 6 ) 1 0 1 – 1 0 7
a r t i c l e i n f o
Article history:
Received 6 October 2015
Received in revised form
15 December 2015
Accepted 27 December 2015
Available online 14 January 2016
Keywords:
NerveCheck
Quantitative sensory testing
Neuropathy
Diagnostic device
Diabetes
a b s t r a c t
Aims: Sensory neuropathy is central to the development of painful neuropathy, and foot
ulceration in patients with diabetes. Currently, available QST devices take considerable time
to perform and are expensive. NerveCheck is the first inexpensive ($500), portable QST
device to perform both vibration and thermal testing and hence evaluate diabetic peripheral
neuropathy (DPN). This study was undertaken to establish the reproducibility and diagnos-
tic validity of NerveCheck for detecting neuropathy.
Methods: 130 subjects (28 with DPN, 46 without DPN and 56 control subjects) underwent QST
assessment with NerveCheck; vibration perception and thermal testing. DPN was defined
according to the Toronto criteria.
Results: NerveCheck’s intra correlation coefficient for vibration, cold and warm sensation
testing was 0.79 (95% LOA: 4.20 to 6.60), 0.86 (95% LOA: 1.38 to 2.72) and 0.71 (95% LOA:
2.36 to 3.83), respectively. The diagnostic accuracy (AUC) for vibration, cold and warm
sensation testing was 86% (SE: 0.038, 95% CI 0.79–0.94), 79% (SE: 0.058, 95% CI 0.68–0.91) and
72% (SE: 0.058, 95% CI 0.60–0.83), respectively.
Conclusions: This study shows that NerveCheck has good reproducibility and comparable
diagnostic accuracy to established QST equipment for the diagnosis of DPN.
# 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Quantitative sensory testing (QST) has been used for decades
for diagnosing and quantifying the severity of DPN [1–5] and
painful neuropathy [4,6–11]. Indeed several guidelines endorse
the use of QST for the diagnosis of sensory abnormalities in
diabetic neuropathy [2,12]. QST is an automated psychophysi-
cal method used to test vibration and thermal sensation which
may help to risk stratify patients for the development of
painful neuropathy, foot ulceration and amputation [13].
Easily deployed and inexpensive tests such as the tuning
folk, pin-prick, VibraTip and 10 g monofilament can detect
moderate to severe sensory loss but for early detection of
sensory impairment, particularly in clinical trials, QST is
required. It provides standardised and quantified stimuli
which enable accurate quantification of sensory deficits [14]
for vibration, a large fibre measure and thermal threshold
testing for the detection of small fibre neuropathy [1–3,15].
Several QST devices are established and are primarily used
in clinical research settings. The Neurothesiometer, VSA 3000
(Medoc), Vibrameter (Somedic), Vibration II (Physitemp) and
Sensitometer are handheld devices but only perform vibration
testing. CASE IV (WR Medical Electronics) measures the
function of both vibration and thermal sensation but is large
and expensive, provides a complex output in the form of just
noticeable differences (JND) from a set of 25 standardised
vibratory levels, and requires trained staff. The TSA-II-
NeuroSensory Analyser (Medoc) and Sensor (Medoc) perform
thermal testing only, are expensive and require a laptop to
operate.
NerveCheck was designed to assess vibration (VPT), cold
(CPT), warm (WPT) perception threshold and heat pain
threshold (HPT). It costs $500 and is portable (size:
9.5 cm  6.1 cm  23.6 cm, weighted only 325 g including
battery) as shown in Fig. 1. It applies a series of predefined
Fig. 1 – NerveCheck is a portable inexpensive ($500)
quantitative sensory device designed to assess vibration
(VPT), cold (CPT), warm (WPT) perception threshold and
heat pain threshold (HPT). Its size is
9.5 cm T 6.1 cm T 23.6 cm and weights only 325 g
including battery. Its output is categorical in terms of
degree of abnormality. The test takes from 3 to 10 min,
depending on whether it is a single test or series of tests.
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intensity, heat waveform and ramped stimuli (1 8C/s)) to the
skin using the method of levels. For each stimulus, the subject
reports whether the stimulus was perceived or not or whether
it was painful or not. This method is not dependent on the
reaction time of the subject. Thresholds for all four modalities
are established within 9–13 min.
In the present study we have carefully validated the
diagnostic ability of NerveCheck for assessing VPT, CPT and
WPT in control subjects and patients with diabetes with a
broad range of neuropathy. We have defined the thresholds
and examined the reproducibility and diagnostic validity of
NerveCheck against other established QST devices.
2. Subjects, materials and methods
The participants in the study were recruited from the
Manchester Diabetes Centre, Manchester Royal Infirmary in
Manchester, UK. The study was performed at the NIHR
Wellcome Trust Clinical Research Facility between 7 January
2013 and 19 September 2014. Exclusion criteria included
subjects with communication disorders, cognitive deficits,
severe anxiety, severe depression or history of neuropathy dueto a non-diabetic cause. Control subjects suffering from any
acute or chronic pain condition were excluded. All subjects
were without any pain medication for at least 24 h before the
investigation. This study was approved by the Local Research
Ethics committee and all patients gave informed consent to
take part in the study. The research adhered to the tenets of
the declaration of Helsinki.
2.1. Demographic measures
All study participants underwent assessment of their glycated
haemoglobin (HbA1c), body mass index (BMI), blood pressure
and cholesterol.
2.2. Quantitative sensory testing using NerveCheck
Subject were familiarised with the procedure and allowed to
acclimatise for 10 min in the examination room. NerveCheck
(Phi Med Europe S.L. Barcelona, Spain) applies the method of
levels where a series of predefined stimuli (in terms of
vibration intensity, heat waveform and ramped stimuli (1 8C/
s)) were applied to the skin and for each stimulus the subject
reported whether the stimulus was perceived or not, to
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perception thresholds. There are four kinds of stimuli for
vibration and thermal testing. The VPT has void, mild
(2.7 V), moderate (4.2 V) and strong (6.4 V) with 9 stimuli in
total. The CPT has void, mild (22.4 8C), moderate (17.8 8C)
and strong (9.8 8C) with 5 stimuli in total. The WPT has void,
mild (37 8C), moderate (39.4 8C) and strong (44.7 8C) with 5
stimuli in total. If the null stimulus answered yes constant-
ly, the result was deemed invalid and was repeated.
This method is not dependent on the reaction time of the
subject.
The order of administration of stimuli was vibration
followed by thermal testing. The stimulator was applied with
a constant pressure to the area of skin to be tested. For
vibration testing, the vibratory transducer was placed on the
dorsal surface of the base of the nail of the great toe. For
thermal testing, the thermode (thermoelectric unit with a
surface area of 5 cm  2.5 cm) was placed on the dorsolateral
surface of the foot. The thermode provides accurate con-
trolled minute ramps of cooling and heating at the thermode-
testing surface using the Peltier effect. The administration of
cooling and heating stimuli involve gradual changes in
temperature along a linear ramp to a preset value and after
a specified time return to steady state following an inverse
ramp.
The output is categorical in terms of degree of abnormality.
The more the subject response correctly to the stimuli the
higher the score gets. The normal and abnormal range for VPT
is (12–8 and 7–0) and for CPT and WPT is (6–3 and 2–0). The
higher the grading score, the more sensitive the participant is
to the stimuli. The testing takes 3–13 min, depending on
whether it is a single test or series of tests. More information
about NerveCheck can be found online (http://www.
phimedeurope.com/).
2.3. Quantitative sensory testing using established
devices
Vibration testing was measured using a Neurothesiometer
(Horwell, Scientific Laboratory Supplies, Wilford, Nottingham,
UK) and was placed at the base of the left great toe. The test
was repeated three times and the average value was recorded.
Thermal testing including CPT and WPT was undertaken on
the dorsum of the left foot using the MEDOC TSA-II-
NeuroSensory Analyser (Medoc Ltd. Ramat Yishai 30095,
Israel) and method of limits [16]. The test was repeated four
times and the average value was recorded.
2.4. Neuropathy assessments
All patients underwent an assessment of neuropathy based
on a standard protocol including: NDS to classify partici-
pants into without (NDS 0–2) and with (NDS 3–10) neuropa-
thy [17,18]. Electro-diagnostic studies were undertaken
using a Dantec ‘‘Keypoint’’ system (Dantec Dynamics Ltd.
Bristol, UK) equipped with a DISA temperature regulator to
keep limb temperature constantly between 32 and 35 8C.
Peroneal Motor Nerve Conduction Velocity (PMNCV) was
assessed in the right lower limb by a consultant neuro-
physiologist.2.5. Study definition of diabetic peripheral neuropathy
The Toronto Diabetic Neuropathy Expert group recommenda-
tion was followed to define DPN: (a) abnormal PMNCV (<42 m/
s) [19] and (b) abnormal symptoms (NSP) or signs of
neuropathy, NDS (>2) [18].
2.6. Statistical analysis
We estimated that the minimum sample required to detect
significant difference between the group with and without
vibration sensation loss is 16 subjects and between the group
with and without thermal sensation loss is 26. The sample size
was calculated by means of an unpaired t-test and with a
power of 85%. We examined the distribution of the data by
means of relevant histograms and the Shapiro–Wilk test using
StatsDirect statistical software, version 2.7.9. All data were
expressed as median (5th percentile, 95th percentile). Mann–
Whitney U test was performed to analyse differences between
the medians. A P value <0.05 was considered statistically
significant.
We examined the repeatability of NerveCheck with
intraclass agreement using GraphPad Prism, version 6.05.
The test–retest intervals were from 1 to 8 weeks references.
Receiver operating characteristic (ROC) curve analysis was
used to compare the diagnostic accuracy of NerveCheck
against established QST devices using GraphPad Prism,
version 6.05. ROC curve analysis established the area under
the curve (AUC) to determine the optimal sensitivity and
specificity of the NerveCheck test.
3. Results
3.1. Clinical data
130 subjects (74 with diabetes mellitus (DM) (59 Type 1 DM and
15 Type 2 DM) with median age 55.7 (interquartile range – IQR:
42.9–66.1) and 56 control subjects with median age 43.6
(interquartile range – IQR: 35.7–53.1)) were studied. Of the
diabetic subjects 28 were diagnosed with and 46 without
diabetic peripheral neuropathy (DPN) based on the Toronto
criteria. The demographic and clinical characteristics of the
participants with and without DPN and controls are presented
in Table 1. BMI, HbA1c and cholesterol levels did not differ
between the groups with and without DPN, but age (P < 0.0001),
duration of diabetes (P < 0.0001) and systolic blood pressure
(P = 0.0005) were significantly greater in those with DPN. The
group with DPN had a significantly higher Neuropathy disability
score (NDS) (P < 0.0001) and significantly lower peroneal motor
nerve conduction velocity (PMNCV) (P < 0.0001). In the Nerve-
Check tests, the group with DPN had a significantly lower score
for vibration perception threshold (VPT) (P < 0.0001), cold
perception threshold (WPT) (P < 0.0001) and warm perception
threshold (WPT) (P < 0.0001) compared to those without DPN.
3.2. NerveCheck defined threshold values
To define a threshold value of the NerveCheck grading score
for VPT, CPT and WPT we have used a mean minus 2 standard
Table 1 – Comparison of clinical data of patients with type 1 & 2 diabetes according to the presence or absence of diabetic
peripheral neuropathy (DPN) defined by the Toronto criteria and control subjects. Data are medians (5th percentile, 95th
percentile), P values are derived from a Mann–Whitney U test: P = 0.05 (–), P = 0.001 (=), P = 0.0001 (B), The P values for
subjects with vs without DPN are in the left column, subjects without DPN vs control subjects in the middle column and
subjects with DPN vs control subjects in the right column.
Variables Neuropathy No neuropathy Controls
n 28 46 56
Gender (male/female) 25/17 22/10 26/44
Age 65.6 (42.5, 83.2)B 46.48 (23.5, 71.9) 43.6 (31, 70.3)B
Diabetes duration (years) 46 (4, 60)B 21 (7, 54)
BMI (kg/m2) 26.72 (24, 40.4) 27.13 (21, 37) 25 (19.5, 38.8)–
Systolic BP (mmHg) 151 (116, 218)= 128 (99, 183) 121 (94, 163)B
HbA1c % [mmol/mol] 8.1 (5.3, 11.2)
[65.03 (34, 99)]
7.64 (6.5, 9.5)
[60 (47, 80.1)]B
5.47 (2.6, 6.2)
[36.30 (5.2, 44.3)]B
Cholesterol (mmol/l) 4.5 (3, 6.4) 4.1 (3, 6.4)B 4.95 (3.9, 6.4)–
NDS 6 (2, 10)B 0 (0, 5)– 0 (0, 3)B
PMNCV (m/s) 36.4 (19, 44.5)B 44.4 (39.6, 50)B 48.95 (44.3, 56.5)B
VPT (NerveCheck grading) 0 (0, 12)B 7 (0, 12)– 11.34 (3.48, 12)B
CPT (NerveCheck grading) 2.5 (0, 6)B 6 (3, 6)– 6 (6, 6)B
WPT (NerveCheck grading) 3 (0, 6)B 6 (2, 6) 6 (1, 6)B
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The normal range of the NerveCheck for VPT, CPT and WPT is
4–12 for VPT, 3–6 for CPT and 3–6 for WPT. The total grading
score for VPT, CPT and WPT is 0–12, 0–6 and 0–6, respectively.
3.3. NerveCheck reproducibility
Controls and subjects with diabetes (n = 16) were tested on two
separate occasions to examine the intraclass agreement with
test–retest intervals ranging from 1 to 8 weeks. The Nerve-
Check has good reproducibility as the intraclass agreement for
VPT, CPT and WPT is 0.79 (95% limits of agreement: 4.20 to
6.60), 0.86 (95% limits of agreement: 1.38 to 2.72) and 0.71 (95%
limits of agreement 2.36 to 3.83), respectively.Fig. 2 – ROC curve analysis was used to evaluate the
diagnostic performance of Nervecheck in detecting
sensory loss against the Neurothesiometer for vibration
perception threshold (VPT) (black line) and the TSA-II-
NeuroSensory Analyser (Medoc) for cold perception
threshold (CPT) (dashed line) and warm perception
threshold (WPT) (dotted line) as reference methods for
QST. The grey line is the null value of the ROC curve. The
AUC for VPT was 86% (SE: 0.038, 95% CI 0.79–0.94,
P < 0.0001), for CPT 79% (SE: 0.058, 95% CI 0.68–0.91,
P < 0.0001) and for WPT 72% (SE: 0.058, 95% CI 0.60–0.83,
P < 0.0004).3.4. NerveCheck diagnostic validity for diabetic peripheral
neuropathy
The diagnostic performance of the NerveCheck in detecting
sensory loss measured against established QST devices is
expressed in AUC using ROC curve analysis (Fig. 2). The VPT
and thermal testing were compared against the Neurothesi-
ometer and TSA-II-NeuroSensory Analyser (Medoc), respec-
tively. The AUC for VPT is 86% (SE: 0.038, 95% CI 0.79–0.94,
P < 0.0001), for CPT 79% (SE: 0.058, 95% CI 0.68–0.91, P < 0.0001)
and for WPT 72% (SE: 0.058, 95% CI 0.60–0.83, P < 0.0004).
The VPT of the NerveCheck displayed high sensitivity 84%
(95% CI 63.92–95.46%) and high specificity 81% (95% CI 72.07–
87.66%) with a likelihood ratio of 4.36% for the diagnosis of
DPN. The CPT exhibited high sensitivity 89% (95% CI 81.72–
94.23%) and moderate specificity 67% (95% CI 46.04–83.48%)
with likelihood ratio 2.67% for the diagnosis of DPN. The WPT
exhibited high sensitivity 75% (95% CI 65.86–83.14%) and
moderate specificity 66% (95% CI 45.67–82.06%) with likelihood
ratio 2.18% for the diagnosis of DPN.
4. Discussion
Sensory dysfunction precedes painful neuropathy, foot ulcer-
ation and amputation in patients with diabetes [13,18]. Both
sensory loss and threshold values can be measured reliably by
quantitative sensory testing (QST) which provides standar-
dised and quantified stimuli and quantifies the level of
response [14]. QST assessment has recently been shown to
provide accurate assessment of sensation loss without intra-
or inter test differences and has therefore been endorsed as a
useful technique for multicenter clinical trials of neuropathy
[20]. Indeed QST assessment was also recently endorsed for
use in the quantification of sensory deficits by the NeuPSIG
consensus [21]. However, the cost and complex output as well
as methodology to establish deficits has hindered more
widespread use of QST in the clinic. NerveCheck was designed
to measure the vibration (VPT), cold (CPT), warm (WPT) and
heat perception threshold (HPT) and provide a simple
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relation to the severity of neuropathy and hence risk
stratification. It is the first inexpensive ($500), portable
(9.5 cm  6.1 cm  23.6 cm) QST device to perform both
vibration and thermal testing. We have demonstrated good
reproducibility and validity of NerveCheck for assessing
sensory loss compared to established devices and give its far
lower cost we would suggest much wider use in the clinic.
Specifically, NerveCheck has good reproducibility and its
ability to detect sensory loss is highly comparable to
established QST devices.
When interpreting individual QST results based on the
normal range in the NerveCheck grading score, age should be
taken into consideration [22]. The normal range of the
NerveCheck for VPT, CPT and WPT in the current study was
based on our control population with a median age of 43.6. The
normal range in the NerveCheck grading score applies to the
age range 30–72. Indeed there are very few large-scale
reference data sets for QST in older adults [23]. Both vibration
and thermal testing have been reported to be independent of
gender [24]. In the current study we did not evaluate thermal
allodynia or hyperalgesia, as the available normal range for
these heat pain thresholds is highly variable [6,25].
The reproducibility of QST has been a challenge with a
significant variability between sessions in the same patient.
Indeed in a very early study over 30 years ago, Fagius et al.
reported a difference of 150% between assessments using the
method of limits [26]. This problem appears less marked
though with the method of levels [27] and NerveCheck uses
the method of levels where it applies a series of predefined
stimuli over a broad range of intensities. For each stimulus, the
subject reports whether the stimulus was perceived or not or
whether it was painful or not and is not dependent on the
reaction time of the subject. Null stimuli have been included in
the algorithms to reduce bias related to a false response. The
vibration testing of NerveCheck produces low variability and a
factor that may be relevant is that the vibration stimulator is
applied with a constant pressure to the area of skin to be
tested. Additionally, NerveCheck runs the vibration testing
before the thermal testing as assessment of thermal sensation
before vibration testing has been found to increase the risk of
vibration hyperalgesia [28]. Of relevance, several studies have
shown good reproducibility of VPT (intraclass correlation
>0.55) in control subjects and in various patient populations
[3,29]. All said, the thermode of the NerveCheck is a highly
engineered device that can provide cooling and heating
stimuli along a linear ramp to a preset value at the thermode
testing surface using the Peltier mechanism as described by
Dyck et al. [14].
QST is an effective technique for the diagnosis of sensory
neuropathy and also provides a composite of quantitative
measures, which can be deployed to define the severity of
neuropathy. Vibration deficits in the feet suggest large fibre
dysfunction [21] and cold and warm deficits indicate small
fibre dysfunction [21]. Dysfunction of small nerve fibres is
thought to be responsible for many painful peripheral
neuropathies [30]. These small fibre neuropathies cannot be
evaluated using standard electrophysiological testing [1–3,15].
Our study shows that NerveCheck has both high sensitivity
84% and high specificity 81% for vibration testing and highsensitivity and moderate specificity for thermal testing. Of
relevance, studies have reported variable sensitivity of
thermal testing depending on the severity of neuropathy,
27–98% for cold and 22–98% for warm deficits [3], while
vibration testing has 58–84% sensitivity and 51–86% specificity
[31,32].
NerveCheck provides a cost effective means to identify
deficits in vibration and thermal sensation. Both Medoc TSA-II
NeuroSensory Analyser and NerveCheck detect sensory
deficits. The former test provides the patient’s perception
threshold for cold and warm. However, unlike TSA-II-
NeuroSensory Analyser, the NerveCheck indicates whether
the results are normal or abnormal and stratifies the severity
of sensory loss. Additional evaluation may include an
assessment of Neuropathic Impairment Score (NIS), autonom-
ic dysfunction via the Neuropad or the assessment of heart
rate variability to deep breathing [33,34] and small fibre
structural damage using corneal confocal microscopy (CCM) or
skin punch biopsy for intra-epidermal nerve fibre density
(IENFD) [35,36].
In conclusion this is a small but detailed study showing
that NerveCheck has good reproducibility and good diagnostic
accuracy for assessing sensory loss compared to established
QST devices. Clearly larger, prospective studies confirming the
diagnostic ability of NerveCheck are required in diabetic
neuropathy and in other neuropathies. NerveCheck is the first
inexpensive, portable QST device to perform both vibration
and thermal testing and therefore provides new opportunities
for use in the clinic. It could therefore be deployed as an
inexpensive but accurate diagnostic test for diabetic neuropa-
thy in primary care in the developed world and throughout the
developing world; which is set to see an explosion in diabetes
and hence diabetic neuropathy. It could also be deployed in
countries such as India and Brazil for conditions such as
leprosy.
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